HIK Hikma Pharmaceuticals Plc

 

TIDMHIK 
 
 
Hikma Pharmaceuticals Plc 
11 January 2010 
 
 
 
 
     Hikma announces partnership with BioCryst for its pandemic flu product 
 
 
London, 11 January 2009: Hikma Pharmaceuticals PLC ("Hikma") (LSE:HIK) (NASDAQ 
Dubai: HIK), a leading speciality pharmaceutical company, announces that it has 
signed an exclusive agreement to represent BioCryst in respect of its anti-viral 
product peramivir for pandemic flu treatment stockpiling opportunities with 
governments in the Middle East and North Africa ('MENA) region. 
 
Said Darwazah, Hikmas Chief Executive Officer commented: "This agreement 
reinforces our position as the partner of choice in the MENA region. BioCryst 
has received peramivir emergency use enquiries from a number of countries in 
MENA, and we look forward to working with BioCryst to make peramivir available 
during the ongoing influenza pandemic, leveraging our regulatory and commercial 
capabilities across 17 markets in the region." 
 
 
=- ENDS - 
 
 
Enquiries 
Hikma Pharmaceuticals PLC 
Susan Ringdal, Investor Relations Director Tel: +44 (0)20 7399 2760 
 
Brunswick Group 
Jon Coles / Justine McIlroy   Tel: +44 (0)20 7404 5959 
 
 
About peramivir 
Peramivir is an intravenously administered anti-viral agent developed to deliver 
high plasma concentrations to the sites of infection. Discovered by BioCryst, 
peramivir inhibits the interactions of influenza neuraminidase, an enzyme which 
is critical to the spread of influenza within a host. In laboratory tests, 
peramivir has shown activity against multiple influenza strains, including 
pandemic H1N1 swine origin flu viral strains. Peramivir has been studied in over 
1800 patients with complicated and uncomplicated influenza. Shionogi & Co., Ltd. 
has filed for regulatory approval in Japan. On October 23, 2009, BioCryst 
announced that the U.S. Food and Drug Administration (FDA) issued an emergency 
use authorization (EUA) for i.v. peramivir in certain adult and pediatric 
patients with confirmed or suspected 2009 H1N1 influenza A infection who are 
admitted to a hospital. Additional information regarding the peramivir EUA is 
available on the web at: http://www.cdc.gov/h1n1flu/eua/. 
 
BioCryst is currently enrolling patients in two peramivir Phase 3 studies 
intended to support U.S. regulatory approval for influenza. Approximately 300 
study locations are targeted to participate in these studies globally. 
 
About Hikma 
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on 
developing, manufacturing and marketing a broad range of both branded and 
non-branded generic and in-licensed products. Hikma's operations are conducted 
through three businesses: "Branded", "Injectables" and "Generics" based 
principally in the Middle East and North Africa ("MENA") region, where it is a 
market leader, the United States and Europe. In 2008, Hikma achieved revenues of 
$581 million and profit attributable to shareholders of $57 million. For news 
and other information, please visit www.hikma.com. 
 
About the MENA region 
The MENA region has a population of 270 million people and comprises the 
following countries: Morocco, Algeria, Tunis, Libya, Egypt, Sudan, Jordan, 
Lebanon, Syria, Iraq, Kuwait, Bahrain, Qatar, United Arab Emirates, Saudi 
Arabia, Yemen and Oman. 
 
About BioCryst 
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule 
pharmaceuticals that block key enzymes involved in infectious diseases, cancer 
and inflammatory diseases. BioCryst has progressed two novel compounds into 
late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and 
forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous 
T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug 
design, BioCryst continues to discover additional compounds and to progress 
others through pre-clinical and early development to address the unmet medical 
needs of atients and physicians. For more information, please visit the 
Company's Web site at www.biocryst.com. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAFMGMMMMRGGZM 
 

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024